Baker McKenzie’s IP litigation practice has received a shot in the arm, with the firm nabbing a partner from Clayton Utz who has several successful trips to the High Court under his belt, along with two members of his team.
V2food, the CSIRO-backed start-up behind Hungry Jack’s plant-based ‘Rebel Whopper’, has lost its bid to patent a product that changes colour when cooked in order to imitate the “meat experience”.
AstraZeneca has sued Pharmacor over its plans to list a generic version of blockbuster diabetes drug Forxiga on the PBS, but the drug maker will have to defend the validity of the patent, which was struck down by a UK court last year.
Zoetis has been ordered to pay Scidera’s costs of defending an unsuccessful summary dismissal application on a lump sum basis in a dispute over a bovine gene patent, with a judge rejecting its “premature” bid for a set-off.
More than just subjective intention is relevant to the defence of honest concurrent use in trade mark law, non-bank lender Firstmac has told the High Court in its dispute with buy now, pay later giant Zip Co.
Social media darling Hismile has lost a challenge to a trade mark application by MySmile, after failing to prove its rival’s mark was deceptively similar to its own viral dental care brand.
Merck KGaA has failed to block Pfizer’s ‘Abrysvo’ trade mark for its RSV vaccine, with a delegate finding no likelihood of confusion with the mark for Merck’s Mavenclad MS drug despite their visual similarities.
Gaming company Light & Wonder will pay $190 million to settle Aristocrat’s litigation in Australia and the United States alleging it misappropriated trade secrets in developing two poker machines.
Otsuka Pharmaceuticals has asked the High Court to overturn a decision revoking its Abilify patent extension, saying the ruling, which limited the extension-of term scheme to active substances only, will “lead to a groundswell of court proceedings”.
German drug maker Merck KGaA is fighting US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia, five years after their intellectual property spat was settled.